Astec LifeSciences Limited Reports Q1 FY27 Results: Net Loss Narrows to ₹1,870.73 Lakh Consolidated

Astec LifeSciences Limited (CIN: L99999MH1994PLC076236), a Godrej Group subsidiary specializing in agrochemical active ingredients, triazole fungicides, and CDMO solutions, has released its standalone and consolidated financial results for the first quarter ended June 30, 2026.

Despite persistent global chemical industry headwinds, the company recorded a narrowing of net losses on a year-over-year basis, while revenue from operations experienced a slight moderation.

Consolidated Financial Performance

For the quarter ended June 30, 2026, Astec LifeSciences reported consolidated revenue from operations of ₹8,356.43 lakh, down 8.25% compared to ₹9,108.21 lakh in Q1 FY26 and down 47.32% sequentially from ₹15,862.26 lakh reported in Q4 FY26.

Including other income of ₹72.74 lakh, total consolidated income for Q1 FY27 reached ₹8,429.17 lakh, relative to ₹9,158.86 lakh in Q1 FY26.

Expense Breakdown (Consolidated)

Total consolidated expenses for Q1 FY27 stood at ₹10,302.99 lakh, representing a decline from ₹12,460.61 lakh in Q1 FY26 and ₹16,915.63 lakh in Q4 FY26.

Cost of Materials Consumed: Reached ₹7,632.28 lakh, up from ₹5,940.62 lakh in Q1 FY26.

Changes in Inventories: Adjustment of ₹(3,370.38) lakh (inventory increase), compared to ₹447.77 lakh in Q1 FY26.

Other Expenses: Totaled ₹2,561.18 lakh, compared to ₹2,300.02 lakh in Q1 FY26.

Employee Benefits Expense: Recorded at ₹1,599.96 lakh, compared to ₹1,518.41 lakh in Q1 FY26.

Depreciation & Amortisation: Stood at ₹1,106.77 lakh, compared to ₹1,149.41 lakh in Q1 FY26.

Finance Costs: Reduced to ₹773.18 lakh, down from ₹1,104.38 lakh in Q1 FY26.

Net Loss & Key Financial Ratios

Due to operational cost controls, net loss narrowed significantly compared to the corresponding period of the previous fiscal year:

Loss Before Tax (LBT): Stood at ₹(1,873.82) lakh, narrowing by 43.25% from ₹(3,301.75) lakh in Q1 FY26.

Net Loss After Tax: Reported at ₹(1,870.73) lakh (attributable to owners: ₹(1,871.74) lakh), compared to a net loss of ₹(3,302.69) lakh in Q1 FY26.

Total Comprehensive Loss: Stood at ₹(1,859.38) lakh, relative to ₹(3,297.34) lakh in Q1 FY26.

Earnings Per Share (EPS): Basic and Diluted EPS improved to ₹(8.40) per share (face value of ₹10 each), compared to ₹(16.85) in Q1 FY26 and ₹(3.48) in Q4 FY26.

Key Ratios (Consolidated):

Current Ratio: 0.83 (vs 0.78 in Q1 FY26)

Debt Equity Ratio: 0.98 (vs 2.95 in Q1 FY26)

Net Worth: ₹37,235.59 lakh as of June 30, 2026

Operating Margin: (0.80)%

Net Profit Margin: (22.39)%

Standalone Performance Summary

On a standalone basis, Astec LifeSciences reported metrics aligned closely with its consolidated operations:

Revenue from Operations: ₹8,356.43 lakh

Total Income: ₹8,427.28 lakh

Total Expenses: ₹10,305.20 lakh

Loss Before Tax: ₹(1,877.92) lakh (vs ₹(3,305.64) lakh in Q1 FY26)

Net Loss After Tax: ₹(1,873.84) lakh (vs ₹(3,305.64) lakh in Q1 FY26)

Total Comprehensive Loss: ₹(1,861.72) lakh

Standalone EPS: Basic & Diluted EPS stood at ₹(8.41) per share.

Paid-Up Share Capital: Stood at ₹2,228.28 lakh (comprising equity shares of ₹10 face value each).

Shares of Astec LifeSciences Limited was last trading in BSE at Rs. 657.00 as compared to the previous close of Rs. 627.85. The total number of shares traded during the day was 4306 in over 260 trades.

The stock hit an intraday high of Rs. 667.00 and intraday low of 630.35. The net turnover during the day was Rs. 2803301.00.

Source : Equity Bulls

Keywords

AstecLifeSciences INE563J01010 Agrochemicals Q1FY27 Q1FY2027 ResultUpdate